Gyros Protein Technologies Introduces Next Generation Gyrolab Protein A Kit for Biotherapeutics

Kit increases efficiency of residual protein A ligand detection

9 May 2017
Weylan Kiam-Laine
Microbiologist

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, has announced it has launched a new version of its Gyrolab™ Protein A Kit.

The new Protein A Kit offers increased efficiency and throughput for quantification of residual Protein A ligands, with 96 microstructures, this next generation in Protein A detection and quantification offers double the capacity of the previous Gyrolab Mixing CD. Two ready to use versions of the kit – Native Protein A and MabSelect™ Sure – are designed for use with Gyrolab systems, and include an enhanced protocol for automated acid pretreatment of harvested samples from downstream purification of biotherapeutics.

Determination of residual protein A is an essential regulatory requirement for the safety evaluation of biotherapeutics. During the purification of biotherapeutics, Protein A can leach from the chromatography support and co-elute with the therapeutic antibody product. If bound to immunoglobulins, Protein A can increase the risk of adverse reactions.

Mattias Bylund, Product Manager, Gyros Protein Technologies, said: “We are pleased to offer our customers this improved version of our Protein A Kit, enabling them to easily and quickly quantify residual Protein A ligands in the presence of high IgG concentrations. The launch of the new kits forms part of Gyros Protein Technologies’ commitment to developing immunoassay solutions for the bioprocess market.”

Links

Tags